Experience of prophylaxis treatment in children with severe haemophilia

被引:65
|
作者
Yee, TT
Beeton, K
Griffioen, A
Harrington, C
Miners, A
Lee, CA
Brown, SA
机构
[1] UCL Royal Free & Univ Coll Med Sch, Haemophilia Ctr, Dept Primary Care & Populat Sci, London NW3 2QG, England
[2] UCL Royal Free NHS Trust, Haemophilia Ctr, London, England
[3] UCL Royal Free NHS Trust, Haemostasis Unit, London, England
[4] Univ Hertfordshire, Hatfield AL10 9AB, Herts, England
关键词
haemophilia; prophylaxis; joint scores; Port-a-Cath; inhibitor;
D O I
10.1046/j.1365-2516.2002.00630.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The practice of prophylactic treatment of boys with severe haemophilia has been evaluated in our centre. Prophylaxis was started at the median age of 3.7 years (range 0.4-12.7 years) in 38/41 children (93%) under 17 years of age. Median follow-up was 4.1 years (range 0.4-12.7 years). The criteria of primary prophylaxis according to the definition by the European Paediatric Network of Haemophilia Management was fulfilled by 9/38 (24%). Although a majority [76%, 29/38] of the children started prophylaxis after a median number of joint bleeds of 3.5, 70% of the children in this group had clinical joint scores of 0. Intravenous catheter insertion was required at a median age of 15.5 months (range 5-36 months) in 21% of the children, resulting in a catheter infection rate of 1.74 per 1000 catheter days. None developed an inhibitor on prophylaxis and three patients who had low-titre inhibitors (< 5 Bethesda units) prior to prophylaxis had undetectable inhibitors after prophylaxis. The home-treatment training programme required considerable time and cost. As a result, 87% of the children used peripheral venous access and hospital visits declined as prophylaxis became established. Parents' incentives for prophylaxis were that the children undertook many physical activities and sports previously not recommended, there was less parental anxiety and an overall improvement in the quality of life for the whole family.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [41] FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
    Perry, D.
    Berntorp, E.
    Tait, C.
    Dolan, G.
    Holme, P. A.
    Laffan, M.
    Lassila, R.
    Mumford, A.
    Pasi, J.
    Wilde, J.
    Will, A.
    Yee, T. T.
    HAEMOPHILIA, 2010, 16 (01) : 80 - 89
  • [42] North American prophylaxis studies for persons with severe haemophilia: background, rationale and design
    Manco-Johnson, MJ
    Blanchette, VS
    HAEMOPHILIA, 2003, 9 : 44 - 48
  • [43] The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey
    Biss, T. T.
    Chan, A. K.
    Blanchette, V. S.
    Iwenofu, L. N.
    Mclimont, M.
    Carcao, M. D.
    HAEMOPHILIA, 2008, 14 (05) : 923 - 930
  • [44] Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice
    Manco-Johnson, M.
    HAEMOPHILIA, 2007, 13 : 4 - 9
  • [45] Adherence to prophylaxis in adolescents and young adults with severe haemophilia A, a qualitative study with patient
    van Os, S.
    Troop, N.
    Ryder, N.
    Hart, D. P.
    HEALTH PSYCHOLOGY AND BEHAVIORAL MEDICINE, 2018, 6 (01): : 277 - 300
  • [46] Prophylaxis in haemophilia with inhibitors: update from international experience
    Carcao, M.
    Lambert, T.
    HAEMOPHILIA, 2010, 16 : 16 - 23
  • [47] Bleeding episodes and surgical procedures in children and adults with haemophilia A on prophylaxis with emicizumab - The experience of a Portuguese centre
    Catarina Camara, Cristina Catarino
    Felix, Jorge
    Pires, Filipa
    Pereira, Artur
    Rodrigues, Fatima
    Cabecinha, Raquel
    Afonso, Patricia
    Rocha, Elsa
    HAEMOPHILIA, 2024, 30 : 143 - 148
  • [48] Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A
    Risebrough, N.
    Oh, P.
    Blanchette, V.
    Curtin, J.
    Hitzler, J.
    Feldman, B. M.
    HAEMOPHILIA, 2008, 14 (04) : 743 - 752
  • [49] Safety and efficacy of investigator-prescribed BeneFIX® prophylaxis in children less than 6 years of age with severe haemophilia B
    Monahan, P. E.
    Liesner, R.
    Sullivan, S. T.
    Ramirez, M. E.
    Kelly, P.
    Roth, D. A.
    HAEMOPHILIA, 2010, 16 (03) : 460 - 468
  • [50] A standardized treatment regimen for patients with severe haemophilia A undergoing orthopaedic or trauma surgery: a single centre experience
    Hart, Christina
    Heindl, Bernhard
    Spannagl, Michael
    Lison, Susanne
    BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (04) : 396 - 402